{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T10:22:33Z","timestamp":1794565353351,"version":"4.9.1"},"reference-count":67,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","amjmed.com","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.amjmed.2024.01.022","type":"journal-article","created":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T05:26:35Z","timestamp":1707456395000},"page":"406-413","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Buprenorphine for Pain: A Narrative Review and Practical Applications"],"prefix":"10.1016","volume":"137","author":[{"given":"Sara","family":"Spinella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2024.01.022_bib0001","series-title":"Chronic Pain and High-Impact Chronic Pain Among US Adults, 2019. NCHS Data Brief, no 390","author":"Zelaya","year":"2020"},{"issue":"4","key":"10.1016\/j.amjmed.2024.01.022_bib0002","doi-asserted-by":"crossref","first-page":"276","DOI":"10.7326\/M14-2559","article-title":"The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop","volume":"162","author":"Chou","year":"2015","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.amjmed.2024.01.022_bib0003","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/jama.2021.11013","article-title":"Association of dose tapering with overdose or mental health crisis among patients prescribed long-term opioids","volume":"326","author":"Agnoli","year":"2021","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.amjmed.2024.01.022_bib0004","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s40122-019-00143-6","article-title":"A narrative pharmacological review of buprenorphine: a unique opioid for the treatment of chronic pain","volume":"9","author":"Gudin","year":"2020","journal-title":"Pain Ther"},{"key":"10.1016\/j.amjmed.2024.01.022_bib0005","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1093\/bja\/aei145","article-title":"Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats","volume":"94","author":"Dahan","year":"2005","journal-title":"Br J Anaesth"},{"issue":"2","key":"10.1016\/j.amjmed.2024.01.022_bib0006","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/08897077.2017.1381663","article-title":"The conundrum of opioid tapering in long-term opioid therapy for chronic pain: a commentary","volume":"39","author":"Manhapra","year":"2018","journal-title":"Subst Abus"},{"key":"10.1016\/j.amjmed.2024.01.022_bib0007","series-title":"Use of Opioids in the Management of Chronic Pain Work Group","year":"2022"},{"issue":"3","key":"10.1016\/j.amjmed.2024.01.022_bib0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7103a1","article-title":"Clinical practice guideline for prescribing opioids for pain\u2014United States, 2022","volume":"71","year":"2022","journal-title":"MMWR Recomm Rep."},{"key":"10.1016\/j.amjmed.2024.01.022_bib0009","first-page":"pnad 140","article-title":"Increasing buprenorphine access for patients with chronic pain: a quality improvement initiative","author":"Wesolowicz","year":"2023","journal-title":"Pain Med"},{"issue":"2","key":"10.1016\/j.amjmed.2024.01.022_bib0010","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.pmr.2020.02.001","article-title":"Buprenorphine in the treatment of chronic pain","volume":"31","author":"Rudolf","year":"2020","journal-title":"Phys Med Rehabil Clin N Am"},{"issue":"4","key":"10.1016\/j.amjmed.2024.01.022_bib0011","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1093\/pm\/pnz356","article-title":"Understanding buprenorphine for use in chronic pain: expert opinion","volume":"21","author":"Webster","year":"2020","journal-title":"Pain Med"},{"issue":"12","key":"10.1016\/j.amjmed.2024.01.022_bib0012","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s11864-021-00910-8","article-title":"Treating chronic pain with buprenorphine\u2014the practical guide","volume":"22","author":"Case","year":"2021","journal-title":"Curr Treat Options Oncol"},{"issue":"12","key":"10.1016\/j.amjmed.2024.01.022_bib0013","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11916-018-0732-2","article-title":"Buprenorphine for chronic pain: a systemic review","volume":"22","author":"Fishman","year":"2018","journal-title":"Curr Pain Headache Rep"},{"issue":"1","key":"10.1016\/j.amjmed.2024.01.022_bib0014","doi-asserted-by":"crossref","first-page":"27241","DOI":"10.52965\/001c.27241","article-title":"Buprenorphine for chronic pain: a safer alternative to traditional opioids","volume":"9","author":"Dalal","year":"2021","journal-title":"Health Psychol Res"},{"issue":"12","key":"10.1016\/j.amjmed.2024.01.022_bib0015","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s40265-018-0953-z","article-title":"Treating chronic pain: An overview of clinical studies centered on the buprenorphine option","volume":"78","author":"Davis","year":"2018","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.amjmed.2024.01.022_bib0016","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2217\/pmt-2020-0013","article-title":"Buprenorphine buccal film for chronic pain management","volume":"10","author":"Hale","year":"2020","journal-title":"Pain Manag"},{"issue":"5","key":"10.1016\/j.amjmed.2024.01.022_bib0017","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/bja\/ael051","article-title":"Buprenorphine induces ceiling in respiratory depression but not in analgesia","volume":"96","author":"Dahan","year":"2006","journal-title":"Br J Anaesth"},{"issue":"11","key":"10.1016\/j.amjmed.2024.01.022_bib0018","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1097\/j.pain.0000000000000670","article-title":"Efficacy and tolerability of buccal buprenorphine in opioid-experienced patients with moderate to severe chronic low back pain: results of a phase 3, enriched enrollment, randomized withdrawal study","volume":"157","author":"Gimbel","year":"2016","journal-title":"Pain"},{"issue":"4","key":"10.1016\/j.amjmed.2024.01.022_bib0019","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.bja.2017.11.086","article-title":"Efficacy and adverse effects of buprenorphine in acute pain management: systematic review and meta-analysis of randomised controlled trials","volume":"120","author":"White","year":"2018","journal-title":"Br J Anaesth"},{"issue":"1","key":"10.1016\/j.amjmed.2024.01.022_bib0020","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s13181-020-00795-3","article-title":"Opioid overdose deaths with buprenorphine detected in postmortem toxicology: a retrospective analysis","volume":"17","author":"Wightman","year":"2021","journal-title":"J Med Toxicol"},{"issue":"9","key":"10.1016\/j.amjmed.2024.01.022_bib0021","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.23019","article-title":"Polysubstance use among patients treated with buprenorphine from a National Urine Drug Test Database","volume":"4","author":"Saloner","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.amjmed.2024.01.022_bib0022","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/00000542-200607000-00012","article-title":"Naloxone reversal of buprenorphine-induced respiratory depression","volume":"105","author":"van Dorp","year":"2006","journal-title":"Anesthesiology"},{"key":"10.1016\/j.amjmed.2024.01.022_bib0023","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1007\/s11606-020-06251-w","article-title":"Complex persistent opioid dependence with long-term opioids: a gray area that needs definition, better understanding, treatment guidance, and policy changes","volume":"35","author":"Manhapra","year":"2020","journal-title":"J Gen Intern Med"},{"issue":"3","key":"10.1016\/j.amjmed.2024.01.022_bib0024","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/hdi.12622","article-title":"Management of pain in end-stage renal disease patients: short review","volume":"22","author":"Raina","year":"2018","journal-title":"Hemodial Int"},{"issue":"22","key":"10.1016\/j.amjmed.2024.01.022_bib0026","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1001\/jama.2022.17485","article-title":"Association between sublingual buprenorphine-naloxone exposure and dental disease","volume":"328","author":"Etminan","year":"2022","journal-title":"JAMA"},{"issue":"22","key":"10.1016\/j.amjmed.2024.01.022_bib0027","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1001\/archinte.167.22.2469","article-title":"QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial","volume":"167","author":"Wedam","year":"2007","journal-title":"Arch Intern Med"},{"issue":"2","key":"10.1016\/j.amjmed.2024.01.022_bib0028","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1213\/ANE.0000000000002718","article-title":"Treatment of chronic pain with various buprenorphine formulations: a systematic review of clinical studies","volume":"127","author":"Aiyer","year":"2018","journal-title":"Anesth Analg"},{"issue":"1","key":"10.1016\/j.amjmed.2024.01.022_bib0029","first-page":"73","article-title":"Efficacy and safety of opioid analgesics for the management of chronic low back pain: an evidence from Bayesian network meta-analysis","volume":"24","author":"Boya","year":"2021","journal-title":"Pain Physician"},{"issue":"12","key":"10.1016\/j.amjmed.2024.01.022_bib0030","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1093\/pm\/pnaa089","article-title":"Is buprenorphine effective for chronic pain? A systematic review and meta-analysis","volume":"21","author":"Lazaridou","year":"2020","journal-title":"Pain Med"},{"issue":"1","key":"10.1016\/j.amjmed.2024.01.022_bib0031","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1213\/ANE.0000000000006467","article-title":"Analgesic effect of buprenorphine for chronic noncancer pain: a systematic review and meta-analysis of randomized controlled trials","volume":"137","author":"Wong","year":"2023","journal-title":"Anesth Analg"},{"issue":"9","key":"10.1016\/j.amjmed.2024.01.022_bib0032","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.24152","article-title":"Evaluation of buprenorphine rotation in patients receiving long-term opioids for chronic pain: a systematic review","volume":"4","author":"Powell","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"23","key":"10.1016\/j.amjmed.2024.01.022_bib0033","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1001\/jama.2018.18472","article-title":"Opioids for chronic noncancer pain: a systematic review and meta-analysis","volume":"320","author":"Busse","year":"2018","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.amjmed.2024.01.022_bib0034","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0277-9536(96)00221-3","article-title":"Shared decision-making in the medical encounter: what does it mean? (or it takes at least two to tango)","volume":"44","author":"Charles","year":"1997","journal-title":"Soc Sci Med"},{"issue":"8","key":"10.1016\/j.amjmed.2024.01.022_bib0035","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1007\/s11606-018-4490-y","article-title":"Patient-centered pain management communication from the patient perspective","volume":"33","author":"Haverfield","year":"2018","journal-title":"J Gen Intern Med"},{"issue":"12","key":"10.1016\/j.amjmed.2024.01.022_bib0036","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1007\/s11606-023-08212-5","article-title":"Patient-provider shared decision-making, trust, and opioid misuse among US veterans prescribed long-term opioid therapy for chronic pain","volume":"38","author":"Somohano","year":"2023","journal-title":"J Gen Intern Med"},{"issue":"1","key":"10.1016\/j.amjmed.2024.01.022_bib0038","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s11606-021-06967-3","article-title":"Reducing frustration and improving management of chronic pain in primary care: is shared decision-making sufficient?","volume":"37","author":"Matthias","year":"2022","journal-title":"J Gen Intern Med"},{"issue":"3","key":"10.1016\/j.amjmed.2024.01.022_bib0037","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1177\/08897077231190697","article-title":"Harms versus harms: rethinking treatment for patients on long-term opioids","volume":"44","author":"Lagisetty","year":"2023","journal-title":"Subst Abus"},{"issue":"5","key":"10.1016\/j.amjmed.2024.01.022_bib0039","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1093\/pm\/pnz197","article-title":"Limited access to on-label formulations of buprenorphine for chronic pain as compared with conventional opioids","volume":"21","author":"Fishman","year":"2020","journal-title":"Pain Med"},{"key":"10.1016\/j.amjmed.2024.01.022_bib0040","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1093\/pm\/pny139","article-title":"Patient experiences navigating chronic pain management in an integrated health care system: a qualitative investigation of women and men","volume":"19","author":"Driscoll","year":"2018","journal-title":"Pain Med"},{"key":"10.1016\/j.amjmed.2024.01.022_bib0041","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1182\/blood-2022-156459","article-title":"\u2018Buprenorphine, it works so differently:\u2019 adults with sickle cell disease describe their experiences transitioning to buprenorphine for treatment of chronic pain","volume":"140","author":"Loeser","year":"2022","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.amjmed.2024.01.022_bib0042","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.jpain.2021.12.006","article-title":"Arguments for and against a new diagnostic entity for patients with chronic pain on long-term opioid therapy for whom harms outweigh benefits","volume":"23","author":"Edmond","year":"2022","journal-title":"J Pain"},{"key":"10.1016\/j.amjmed.2024.01.022_bib0043","series-title":"BUTRANS [package insert]","year":"2014"},{"key":"10.1016\/j.amjmed.2024.01.022_bib0044","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/MJT.0b013e31828bfb6e","article-title":"Transdermal buprenorphine, opioid rotation to sublingual buprenorphine, and the avoidance of precipitated withdrawal: a review of the literature and demonstration in three chronic pain patients treated with butrans","volume":"22","author":"Kornfeld","year":"2015","journal-title":"Am J Ther"},{"key":"10.1016\/j.amjmed.2024.01.022_bib0045","first-page":"1023","article-title":"Rapid transition from methadone to buprenorphine utilizing a micro-dosing protocol","volume":"39","author":"DeAquino","year":"2018","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.amjmed.2024.01.022_bib0046","first-page":"24","article-title":"Rapid induction therapy for opioid use disorder using buprenorphine transdermal patch: a case series","author":"Saal","year":"2020","journal-title":"Perm J"},{"key":"10.1016\/j.amjmed.2024.01.022_bib0047","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/02024458-201706000-00006","article-title":"Case report: high-dose methadone transition to buprenorphine\/naloxone in an inpatient with a prolonged QT interval","volume":"8","author":"Cortina","year":"2017","journal-title":"Can J Addict"},{"issue":"5","key":"10.1016\/j.amjmed.2024.01.022_bib0048","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/j.1521-0391.2011.00159.x","article-title":"Transdermal buprenorphine to switch patients from higher dose methadone to buprenorphine without severe withdrawal symptoms","volume":"20","author":"Hess","year":"2011","journal-title":"Am J Addict"},{"issue":"1","key":"10.1016\/j.amjmed.2024.01.022_bib0049","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1080\/00325481.2017.1270156","article-title":"Effects of buprenorphine on QT intervals in healthy subjects: results of 2 randomized positive- and placebo-controlled trials","volume":"129","author":"Harris","year":"2017","journal-title":"Postgrad Med"},{"issue":"10","key":"10.1016\/j.amjmed.2024.01.022_bib0050","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1093\/pm\/pnx235","article-title":"Converting from transdermal to buccal formulations of buprenorphine: a pharmacokinetic meta-model simulation in healthy volunteers","volume":"19","author":"Priestley","year":"2018","journal-title":"Pain Med"},{"key":"10.1016\/j.amjmed.2024.01.022_bib0051","series-title":"BELBUCA [package insert]","year":"2015"},{"issue":"3","key":"10.1016\/j.amjmed.2024.01.022_bib0052","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/ADM.0000000000000745","article-title":"Hospital-based buprenorphine micro-dose initiation","volume":"15","author":"Weimer","year":"2021","journal-title":"J Addict Med"},{"issue":"5","key":"10.1016\/j.amjmed.2024.01.022_bib0053","first-page":"899","article-title":"Evaluation of the tolerability of switching patients on chronic full \u03bc-opioid agonist therapy to buccal buprenorphine","volume":"17","author":"Webster","year":"2016","journal-title":"Pain Med"},{"issue":"2S Suppl 1","key":"10.1016\/j.amjmed.2024.01.022_bib0054","first-page":"1","article-title":"The ASAM National Practice guideline for the treatment of opioid use disorder: 2020 focused update","volume":"14","year":"2020","journal-title":"J Addict Med"},{"key":"10.1016\/j.amjmed.2024.01.022_bib0055","series-title":"SUBOXONE [package insert]","year":"2010"},{"issue":"2","key":"10.1016\/j.amjmed.2024.01.022_bib0056","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s11606-008-0866-8","article-title":"Home buprenorphine\/naloxone induction in primary care","volume":"24","author":"Lee","year":"2009","journal-title":"J Gen Intern Med"},{"issue":"5","key":"10.1016\/j.amjmed.2024.01.022_bib0057","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.addbeh.2010.01.001","article-title":"Unobserved versus observed office buprenorphine\/naloxone induction: a pilot randomized clinical trial","volume":"35","author":"Gunderson","year":"2010","journal-title":"Addict Behav"},{"issue":"4","key":"10.1016\/j.amjmed.2024.01.022_bib0058","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jsat.2010.12.002","article-title":"A comparison of buprenorphine induction strategies: patient-centered home-based inductions versus standard-of-care office-based inductions","volume":"40","author":"Cunningham","year":"2011","journal-title":"J Subst Abuse Treat"},{"issue":"4","key":"10.1016\/j.amjmed.2024.01.022_bib0059","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/ajad.13135","article-title":"Microinduction of buprenorphine\/naloxone: a review of the literature","volume":"30","author":"Ahmed","year":"2021","journal-title":"Am J Addict"},{"issue":"3","key":"10.1016\/j.amjmed.2024.01.022_bib0060","first-page":"427","article-title":"Initiating opioid agonist treatment for opioid use disorder in the inpatient setting: a teachable moment","volume":"179","author":"Raheemullah","year":"2019","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.amjmed.2024.01.022_bib0061","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/ADM.0000000000000745","article-title":"Hospital-based buprenorphine micro-dose initiation","volume":"15","author":"Weimer","year":"2021","journal-title":"J Addict Med"},{"issue":"1","key":"10.1016\/j.amjmed.2024.01.022_bib0062","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s11606-019-05514-5","article-title":"Provider misinterpretation, documentation, and follow-up of definitive urine drug testing results","volume":"35","author":"Chua","year":"2020","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.amjmed.2024.01.022_bib0063","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.drugalcdep.2018.05.033","article-title":"Racial disparities in discontinuation of long-term opioid therapy following illicit drug use among black and white patients","volume":"192","author":"Gaither","year":"2018","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.amjmed.2024.01.022_bib0064","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.drugalcdep.2019.06.015","article-title":"Urine is superior to oral fluid for detecting buprenorphine compliance in patients undergoing treatment for opioid addiction","volume":"203","author":"Ransohoff","year":"2019","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.amjmed.2024.01.022_bib0065","article-title":"Association between buprenorphine dose and the urine \u201cnorbuprenorphine\u201d to \u201ccreatinine\u201d ratio: revised","volume":"17","author":"Furo","year":"2023","journal-title":"Subst Abuse"},{"key":"10.1016\/j.amjmed.2024.01.022_bib0066","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.drugalcdep.2017.07.040","article-title":"Interpreting quantitative urine buprenorphine and norbuprenorphine levels in office-based clinical practice","volume":"180","author":"Donroe","year":"2017","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"10.1016\/j.amjmed.2024.01.022_bib0067","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1111\/pme.12740","article-title":"Interpretation of urine drug testing results in patients using transdermal buprenorphine preparations for the treatment of chronic noncancer pain","volume":"16","author":"Markman","year":"2015","journal-title":"Pain Med"},{"issue":"6","key":"10.1016\/j.amjmed.2024.01.022_bib0068","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/ADM.0000000000000789","article-title":"Discontinuing methadone and buprenorphine: a review and clinical challenges","volume":"15","author":"Zweben","year":"2021","journal-title":"J Addict Med"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934324000561?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934324000561?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T11:26:29Z","timestamp":1714217189000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934324000561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":67,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S0002934324000561"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2024.01.022","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Buprenorphine for Pain: A Narrative Review and Practical Applications","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2024.01.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}